334970 — Prestige Biologics Income Statement
0.000.00%
Last trade - 00:00- KR₩97bn
- KR₩192bn
- KR₩27bn
Annual income statement for Prestige Biologics, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 6 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.6 | 1,730 | 2,169 | 12,533 | 26,665 |
| Cost of Revenue | |||||
| Gross Profit | 3.6 | 518 | -8,687 | -15,686 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 37,293 | 23,836 | 35,599 | 46,215 | — |
| Operating Profit | -37,277 | -22,105 | -33,430 | -33,682 | — |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -49,718 | -17,980 | -29,374 | -27,469 | -51,220 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -49,718 | -17,980 | -29,374 | -27,469 | — |
| Net Income Before Extraordinary Items | |||||
| Net Income | -49,718 | -17,980 | -29,374 | -27,469 | — |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49,718 | -17,980 | -29,374 | -27,469 | — |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -950 | -294 | -481 | -372 | — |
| Dividends per Share |